The Patent Finder

Compugen Ltd.

17 patents currently held · Updated Nov 19, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Feb 2036
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Jan 16 to 18, 2027 · next Jan 16
  • 2 fees due Apr 24, 2027
  • 1 fee due Aug 4, 2027
    The maintenance fee for PVRIG polypeptides and methods of treatment (US 10,550,173) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 21, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,714,289Anti-Pvrig Antibodies and Methods of Use
In force
 · Medium confidence
In forceMedium confidence
US 10,351,625Anti-Pvrig Antibodies and Methods of Use
In force
 · Medium confidence
In forceMedium confidence
US 11,220,542Anti-Pvrig Antibodies and Methods of Use
In force
 · Medium confidence
In forceMedium confidence
US 11,623,955Anti-Pvrig Antibodies and Methods of Use
In force
 · Medium confidence
In forceMedium confidence
US 11,795,220Anti-Pvrig Antibodies and Methods of Use
In force
 · Medium confidence
In forceMedium confidence
US 12,312,404Anti-Pvrig Antibodies and Methods of Use
In force
 · Medium confidence
In forceMedium confidence
US 10,227,408Anti-Pvrig Antibodies and Methods of Use
In force
 · Medium confidence
In forceMedium confidence
US 10,550,173PVRIG polypeptides and methods of treatment
In force
 · USPTO record
In forceUSPTO record
US 11,795,209PVRIG polypeptides and methods of treatment
In force
 · USPTO record
In forceUSPTO record
US 10,124,061Anti-Tigit Antibodies, Anti-Pvrig Antibodies and Combinations Thereof
In force
 · Low confidence
In forceLow confidence
10 of 17 patents shown.
Pro members see all 17.
Pro members: see all 17 patents
Also on record, not counted in the 17: 40 lapsed for an unpaid fee · 5 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

10 pending · 35 abandoned · 29 no status recorded

Showing 1 to 10 of 74, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/190,452Anti-Pvrig Antibodies and Methods of UseApr 25, 2025Pending
18/774,872Triple Combination Antibody TherapiesJul 16, 2024Pending
18/754,029IL-18BP Antagonist Antibodies and Their Use in Monotherapy and Combination Therapy in the Treatment of CancerJun 25, 2024Pending
18/460,523Sep 1, 2023No status recorded
18/460,276HIDE1 Compositions and MethodsSep 1, 2023Abandoned
18/452,985Anti-Tigit Antibodies, Anti-Pvrig Antibodies and Combinations ThereofAug 21, 2023Pending
18/185,632PVRL2 And/Or Pvrig as Biomarkers for TreatmentMar 17, 2023Abandoned
18/846,112IL-18BP Antagonist Antibodies and Their Use in Monotherapy and Combination Therapy in the Treatment of CancerMar 15, 2023Pending
18/700,194Combination Therapy with Anti-Pvrig Antibodies Formulations, Anti-Tigit Antibodies, and ANTI-PD-1 AntibodiesOct 17, 2022Pending
18/572,125Anti-Tigit and Anti-Pvrig in Monotherapy and Combination TreatmentsJul 1, 2022Pending
10 of 74 applications shown.
Pro members see all 74 published applications.
Pro members: see all 74 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited